Anxiety enhances pain in a model of osteoarthritis and is associated with altered endogenous opioid function and reduced opioid analgesia
STEPHEN WOODHAMS STEPHEN.WOODHAMS@NOTTINGHAM.AC.UK
David J. G. Watson
LI LI email@example.com
Senior Research Fellow
James J. Burston
Peter R. W. Gowler
MERITXELL CANALS M.CANALS@NOTTINGHAM.AC.UK
Professor of Cellular Pharmacology
DAVID WALSH firstname.lastname@example.org
Professor of Rheumatology
GARETH HATHWAY email@example.com
Professor VICTORIA CHAPMAN VICTORIA.CHAPMAN@NOTTINGHAM.AC.UK
Professor of Neuropharmacology
Negative affect, including anxiety and depression, is prevalent in chronic pain states such as osteoarthritis (OA) and associated with greater use of opioid analgesics, potentially contributing to present and future opioid crises.
We tested the hypothesis that the interaction between anxiety, chronic pain, and opioid use results from altered endogenous opioid function.
A genetic model of negative affect, the Wistar–Kyoto (WKY) rat, was combined with intra-articular injection of monosodium iodoacetate (MIA; 1 mg) to mimic clinical presentation. Effects of systemic morphine (0.5–3.5 mg·kg−1) on pain behaviour and spinal nociceptive neuronal activity were compared in WKY and normo-anxiety Wistar rats 3 weeks after MIA injection. Endogenous opioid function was probed by the blockade of opioid receptors (0.1–1 mg·kg−1 systemic naloxone), quantification of plasma β-endorphin, and expression and phosphorylation of spinal mu-opioid receptor (MOR).
Monosodium iodoacetate–treated WKY rats had enhanced OA-like pain, blunted morphine-induced analgesia, and greater mechanical hypersensitivity following systemic naloxone, compared with Wistar rats, and elevated plasma β-endorphin levels compared with saline-treated WKY controls. Increased MOR phosphorylation at the master site (serine residue 375) in the spinal cord dorsal horn of WKY rats with OA-like pain (P = 0.0312) indicated greater MOR desensitization.
Reduced clinical analgesic efficacy of morphine was recapitulated in a model of high anxiety and OA-like pain, in which endogenous opioid tone was altered, and MOR function attenuated, in the absence of previous exogenous opioid ligand exposure. These findings shed new light on the mechanisms underlying the increased opioid analgesic use in high anxiety patients with chronic pain.
Lillywhite, A., Woodhams, S. G., Gonçalves, S. V., Watson, D. J. G., Li, L., Burston, J. J., …Chapman, V. (2021). Anxiety enhances pain in a model of osteoarthritis and is associated with altered endogenous opioid function and reduced opioid analgesia. PAIN Reports, 6(4), Article e956. https://doi.org/10.1097/PR9.0000000000000956
|Journal Article Type||Article|
|Acceptance Date||Aug 2, 2021|
|Online Publication Date||Nov 12, 2021|
|Publication Date||Nov 1, 2021|
|Deposit Date||Aug 20, 2021|
|Publicly Available Date||Nov 1, 2021|
|Publisher||Lippincott, Williams & Wilkins|
|Peer Reviewed||Peer Reviewed|
Anxiety Opioid Analgesia In Chronic Pain
Publisher Licence URL